Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002007512 | SCV002230553 | pathogenic | Tumor predisposition syndrome 3 | 2022-02-20 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant is also known as c.281_282del. This premature translational stop signal has been observed in individual(s) with cutaneous melanoma and uveal melanoma (PMID: 32907878). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln94Glyfs*13) in the POT1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POT1 are known to be pathogenic (PMID: 32155570). |
Ambry Genetics | RCV003382750 | SCV004091460 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-07-10 | criteria provided, single submitter | clinical testing | The c.279_280delTC pathogenic mutation, located in coding exon 4 of the POT1 gene, results from a deletion of two nucleotides at nucleotide positions 279 to 280, causing a translational frameshift with a predicted alternate stop codon (p.Q94Gfs*13). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |